PMID- 35399230
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 14
IP  - 3
DP  - 2022 Mar
TI  - A retrospective cohort study of sintilimab and pembrolizumab as first-line 
      treatments for advanced non-small cell lung cancer.
PG  - 679-688
LID - 10.21037/jtd-22-225 [doi]
AB  - BACKGROUND: Pembrolizumab and sintilimab have both been approved by the China 
      National Medical Products Administration (NMPA) for the first-line treatment of 
      advanced non-small cell lung cancer (NSCLC). These two drugs have several 
      differences in biological characteristics and population in clinical trials. The 
      current retrospective study was conducted to compare the efficacy and safety of 
      sintilimab and pembrolizumab as first-line treatments in patients with advanced 
      NSCLC. METHODS: Consecutive patients with advanced NSCLC who received sintilimab 
      or pembrolizumab as first-line therapy, with or without chemotherapy, from 
      November 2018 to October 2021 in the First Affiliated Hospital of Soochow 
      University and Dushu Lake Hospital Affiliated to Soochow University were 
      retrospectively reviewed. Clinical data and treatment response were collected and 
      survival was followed up. Kaplan-Meier method was used to estimate survival 
      curves. The patients were divided into the sintilimab group and the pembrolizumab 
      group according to the PD-1 inhibitors they received during treatment. The 
      primary objective was to compare objective response rate (ORR) and 
      progression-free survival (PFS) between the two groups. The secondary objectives 
      were to compare disease control rate (DCR) and analyze adverse events (AEs) of 
      the two groups. RESULTS: A total of 124 patients were enrolled, including 68 
      patients (54.8%) in the sintilimab group and 56 patients (45.2%) in the 
      pembrolizumab group. The baseline characteristics of the patients were comparable 
      between the two groups. The ORR was 50% in the sintilimab group and 46.4% in the 
      pembrolizumab group (P=0.69). The DCR was 89.7% and 89.3% in the sintilimab group 
      and the pembrolizumab group, respectively (P=0.94). The median PFS time was 9.9 
      months in patients treated with sintilimab compared to 10.8 months in patients on 
      pembrolizumab treatment [hazard ratio (HR) =0.960; 95% confidence interval (CI): 
      0.574-1.606; P=0.875]. The median OS time was not reached in either group of 
      patients. The incidence of grade 3-4 treatment-related adverse events (TRAEs) was 
      25% (17/68) in the sintilimab group and 21.4% (12/56) in the pembrolizumab group. 
      CONCLUSIONS: Sintilimab has similar efficacy to pembrolizumab as a first-line 
      treatment option for patients with advanced NSCLC in clinical practice, with 
      manageable AEs.
CI  - 2022 Journal of Thoracic Disease. All rights reserved.
FAU - Wu, Kai
AU  - Wu K
AD  - Department of Pulmonary and Critical Care Medicine, Dushu Lake Hospital 
      Affiliated to Soochow University, Suzhou, China.
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital 
      of Soochow University, Suzhou, China.
FAU - Fu, Yifan
AU  - Fu Y
AD  - Department of Pulmonary and Critical Care Medicine, Dushu Lake Hospital 
      Affiliated to Soochow University, Suzhou, China.
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital 
      of Soochow University, Suzhou, China.
FAU - Zeng, Daxiong
AU  - Zeng D
AD  - Department of Pulmonary and Critical Care Medicine, Dushu Lake Hospital 
      Affiliated to Soochow University, Suzhou, China.
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital 
      of Soochow University, Suzhou, China.
FAU - Chen, Tao
AU  - Chen T
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital 
      of Soochow University, Suzhou, China.
FAU - Wang, Changguo
AU  - Wang C
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital 
      of Soochow University, Suzhou, China.
FAU - Jiang, Junhong
AU  - Jiang J
AD  - Department of Pulmonary and Critical Care Medicine, Dushu Lake Hospital 
      Affiliated to Soochow University, Suzhou, China.
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital 
      of Soochow University, Suzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC8987820
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - efficacy
OT  - pembrolizumab
OT  - safety
OT  - sintilimab
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jtd.amegroups.com/article/view/10.21037/jtd-22-225/coif). All authors 
      report this study was funded by the Suzhou Science and Technology Project (No. 
      SLT201917). The authors have no other conflicts of interest to declare.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
PMCR- 2022/03/01
CRDT- 2022/04/11 05:11
PHST- 2022/01/21 00:00 [received]
PHST- 2022/03/14 00:00 [accepted]
PHST- 2022/04/11 05:11 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - jtd-14-03-679 [pii]
AID - 10.21037/jtd-22-225 [doi]
PST - ppublish
SO  - J Thorac Dis. 2022 Mar;14(3):679-688. doi: 10.21037/jtd-22-225.